YU68900A - Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka - Google Patents

Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka

Info

Publication number
YU68900A
YU68900A YU68900A YU68900A YU68900A YU 68900 A YU68900 A YU 68900A YU 68900 A YU68900 A YU 68900A YU 68900 A YU68900 A YU 68900A YU 68900 A YU68900 A YU 68900A
Authority
YU
Yugoslavia
Prior art keywords
combinations
hmg coa
cancer
theat
coa reductase
Prior art date
Application number
YU68900A
Other languages
English (en)
Inventor
Judith Leopold
Roger Schofiled Newton
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU68900A publication Critical patent/YU68900A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Opisane su nove kombinacije inhibitora enzima protein farnesiltransferaze i enzima HMG CoA reduktaze, kao i postupci za dobijanje farmaceutskih preparata od istih, koji su korisni u prevenciji ili tretiranju raka, restenoze, psorijaze, emdometrioze, ateroskleroze ili virusnih infekcija.[Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
YU68900A 1998-05-12 1999-05-10 Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka YU68900A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8520298P 1998-05-12 1998-05-12
US9225398P 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
YU68900A true YU68900A (sh) 2002-12-10

Family

ID=26772425

Family Applications (1)

Application Number Title Priority Date Filing Date
YU68900A YU68900A (sh) 1998-05-12 1999-05-10 Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka

Country Status (26)

Country Link
US (1) US6492410B1 (sh)
EP (1) EP1077949A2 (sh)
JP (1) JP2002514628A (sh)
KR (1) KR20010043529A (sh)
CN (1) CN1171874C (sh)
AP (1) AP2000001984A0 (sh)
AU (1) AU758891B2 (sh)
BG (1) BG105003A (sh)
BR (1) BR9911785A (sh)
CA (1) CA2331295A1 (sh)
EA (1) EA003860B1 (sh)
EE (1) EE200000660A (sh)
GE (1) GEP20032996B (sh)
HK (1) HK1038355A1 (sh)
HR (1) HRP20000771A2 (sh)
HU (1) HUP0102322A3 (sh)
ID (1) ID27933A (sh)
IL (1) IL139502A0 (sh)
IS (1) IS5713A (sh)
NO (1) NO20005680L (sh)
NZ (1) NZ508357A (sh)
OA (1) OA11551A (sh)
PL (1) PL344662A1 (sh)
SK (1) SK16742000A3 (sh)
WO (1) WO1999058505A2 (sh)
YU (1) YU68900A (sh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2991700A (en) * 1999-02-11 2000-08-29 Hollis-Eden Pharmaceuticals, Inc. Methods for treating viral infections
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2005042710A1 (en) * 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
KR100930365B1 (ko) * 2006-11-09 2009-12-08 덕성여자대학교 산학협력단 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
NL9002031A (nl) 1990-09-14 1992-04-01 Voskuilen Woudenberg Bv Inrichting voor het bewerken van een uitwendig buisoppervlak.
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
JPH11508262A (ja) 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
AU711104B2 (en) * 1995-06-22 1999-10-07 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування

Also Published As

Publication number Publication date
IL139502A0 (en) 2001-11-25
AP2000001984A0 (en) 2000-12-31
EP1077949A2 (en) 2001-02-28
AU758891B2 (en) 2003-04-03
HRP20000771A2 (en) 2001-06-30
KR20010043529A (ko) 2001-05-25
HUP0102322A3 (en) 2001-12-28
NO20005680D0 (no) 2000-11-10
WO1999058505A3 (en) 2000-01-06
HUP0102322A2 (hu) 2001-11-28
EA003860B1 (ru) 2003-10-30
EA200001164A1 (ru) 2001-06-25
ID27933A (id) 2001-05-03
PL344662A1 (en) 2001-11-19
BG105003A (en) 2001-07-31
IS5713A (is) 2000-11-10
EE200000660A (et) 2002-04-15
US6492410B1 (en) 2002-12-10
NO20005680L (no) 2001-01-10
GEP20032996B (en) 2003-06-25
BR9911785A (pt) 2001-04-03
NZ508357A (en) 2002-09-27
AU3979299A (en) 1999-11-29
WO1999058505A2 (en) 1999-11-18
OA11551A (en) 2004-05-24
CA2331295A1 (en) 1999-11-18
CN1306515A (zh) 2001-08-01
HK1038355A1 (en) 2002-03-15
CN1171874C (zh) 2004-10-20
SK16742000A3 (sk) 2001-07-10
JP2002514628A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
BR0010220A (pt) Compostos de pirimidinona
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
HRP950337B1 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2288948A1 (en) Modified arginine deiminase
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
NO308250B1 (no) 6-Arylpyrido[2,3-d]pyrimidiner og -naftyridiner og farmasøytiske preparater omfattende disse
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
YU68900A (sh) Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
WO2001014584A3 (en) Methods of identifying anti-viral agents
BG103832A (en) Leptin as tumour cells proliferation inhibitor
WO1996034113A3 (en) Methods for the identification of farnesyltransferase inhibitors
AU2001259353A1 (en) Novel mutated form of arginine deiminase
WO2002044360A3 (en) Modified arginine deiminase
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2002030941A3 (en) Topoisomerase inhibitors
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
BR0114884A (pt) Compostos calcilìticos
PT951471E (pt) Inibidores cicloalquilo de farnesiltransferase de proteinas
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi